Clinical trial · Interventional
The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study
NCT01842750CI-TRIAL-00015248BRADunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to test the hypothesis that insertion of an endorectal balloon into a patient receiving radical prostate radiotherapy by treatment radiographers is feasible without the patient experiencing undue discomfort. In addition this study will test the hypotheses that insertion of the rectal balloon prior to radiotherapy delivery stabilises rectal volume during radiotherapy treatment and minimises organ motion within the pelvis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endorectal Balloon insertion | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Endorectal Balloon insertion
- description
- A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.
- interventionNames
- Device: Endorectal Balloon insertion
Primary outcomes (1)
- measure
- Tolerability
- timeFrame
- Patients will be assessed for 4 weeks throughout radiotherapy treatment
- description
- The primary aim is to determine whether the balloon insertion is tolerated throughout treatment. The principle outcome measure is the percentage of patients who tolerate the endorectal balloon throughout treatment.
Secondary outcomes (4)
- measure
- rectal volume
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than or equal to 18 years * ECOG performance status 0-2 (Patients with PS-2 as a result of comorbidity will be excluded). * Patients with histologically confirmed diagnosis of prostate adenocarcinoma * Patients who are going to undergo treatment with radical radiotherapy for prostate cancer. * Patients must be able to receive and understand verbal and written information regarding the study and give written, informed consent * Patients must be able to comply with trial requirements. Exclusion Criteria: * Patients must not have a history of previous bowel surgery involving the rectum or anus. * Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the trial, as well as any other serious uncontrolled medical condition. * Any patient with a medical or psychiatric condition that impairs their ability to give informed consent * Pre-existing anorectal disease, e.g. Haemorrhoids, active bleeding, anal irritation, inflammatory bowel disease. * Patients who are unable to give consent. * Patients in clinical trials of new investigational medicinal products or treatment regimens unless there is written, prior agreement that the patient can also consent to this study, and that clinical data can also be used for this study. * Prior pelvic radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.